Carl Zeiss Meditec Stock Shares Outstanding

CZMWF Stock  USD 59.30  4.43  8.07%   
Carl Zeiss Meditec fundamentals help investors to digest information that contributes to Carl Zeiss' financial success or failures. It also enables traders to predict the movement of Carl Pink Sheet. The fundamental analysis module provides a way to measure Carl Zeiss' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Carl Zeiss pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Carl Zeiss Meditec Company Shares Outstanding Analysis

Carl Zeiss' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.

Shares Outstanding

 = 

Public Shares

-

Repurchased

More About Shares Outstanding | All Equity Analysis

Current Carl Zeiss Shares Outstanding

    
  89.44 M  
Most of Carl Zeiss' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Carl Zeiss Meditec is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition

Based on the latest financial disclosure, Carl Zeiss Meditec has 89.44 M of shares currently outstending. This is 50.46% lower than that of the Healthcare sector and 4.12% higher than that of the Medical Instruments & Supplies industry. The shares outstanding for all United States stocks is 84.36% higher than that of the company.

Carl Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Carl Zeiss' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Carl Zeiss could also be used in its relative valuation, which is a method of valuing Carl Zeiss by comparing valuation metrics of similar companies.
Carl Zeiss is currently under evaluation in shares outstanding category among its peers.

Carl Fundamentals

About Carl Zeiss Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Carl Zeiss Meditec's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Carl Zeiss using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Carl Zeiss Meditec based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Carl Pink Sheet

Carl Zeiss financial ratios help investors to determine whether Carl Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Carl with respect to the benefits of owning Carl Zeiss security.